Rifaximin and lubiprostone: the best options for treating irritable bowel syndrome?

Expert Rev Gastroenterol Hepatol. 2012 Jun;6(3):263. doi: 10.1586/egh.12.21.
No abstract available

Publication types

  • News

MeSH terms

  • Alprostadil / adverse effects
  • Alprostadil / analogs & derivatives*
  • Alprostadil / therapeutic use
  • Gastrointestinal Agents / adverse effects
  • Gastrointestinal Agents / therapeutic use*
  • Humans
  • Irritable Bowel Syndrome / drug therapy*
  • Lubiprostone
  • Rifamycins / adverse effects
  • Rifamycins / therapeutic use*
  • Rifaximin
  • Treatment Outcome

Substances

  • Gastrointestinal Agents
  • Rifamycins
  • Lubiprostone
  • Alprostadil
  • Rifaximin